Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Non-metastatic Prostate Cancer × enzalutamide × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 191 Neoplasm Metastasis 22 Prostatic Neoplasms, Castration-Resistant 20 Breast Neoplasms 19 Neoplasms 17 Metastatic Castration Resistant Prostate Cancer 10 Prostate Cancer Metastatic 7 Metastatic Castration-Resistant Prostate Cancer 7 Triple Negative Breast Neoplasms 6 Metastatic Castration-resistant Prostate Cancer 6 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 Pancreatic Neoplasms 5 Castration-resistant Prostate Cancer 5 Carcinoma, Non-Small-Cell Lung 5 Melanoma 4 Colorectal Neoplasms 4 Bulbo-Spinal Atrophy, X-Linked 4 Urinary Bladder Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Small Cell Lung Carcinoma 3 Prostate Adenocarcinoma 3 Ovarian Neoplasms 3 Carcinoma, Hepatocellular 3 Adenocarcinoma 3 mCRPC 2 Uterine Cervical Neoplasms 2 Recurrence 2 Prostatic Diseases 2 Non-metastatic Castration-resistant Prostate Cancer 2 Metastatic Hormone-sensitive Prostate Cancer 2

Interventions

enzalutamide 1 darolutamide 1 apalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06204302 2024-04-09

ARENA

Bayer

Non-metastatic Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡